Novartis’ breast cancer drug cuts risk of death by 19 percent after six years, data shows

LONDON: Swiss drugmaker Novartis’ drug Kisqali helped extend survival for women with a form of high-risk, early-stage breast cancer, cutting their risk of death by 19 percent…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.arabnews.com)